Has tepotinib been included in the national medical insurance?

Tepotinib is a targeted therapy drug mainly used to treat non-small cell lung cancer (NSCLC) with MET gene mutations. The drug inhibits the activity of METkinase, thereby preventing the growth and spread of tumor cells. It has a significant therapeutic effect especially on tumors with MET amplification or MET mutations. Tepotinib has been launched in China and has been successfully included in my country's medical insurance system, which provides a more affordable option for patients who need to receive treatment with this drug.

In China, the price of the original drug Tepotinib is relatively high, with the market price being about more than 30,000 yuan per box. The specific cost may vary according to different hospitals and regions. Nonetheless, patients can reduce their financial burden through health insurance reimbursement policies. However, some patients may still face financial pressure due to the high price of tepotinib, so price often becomes an important factor for patients to consider when choosing a drug.

In overseas markets, especially the Laos market, patients can also choose generic versions of tepotinib. The price of generic tepotinib produced by Lao Lucius and Lao Daxiong companies is relatively low, and the price has even been lowered recently to more than 6,000 yuan. This price is much cheaper than the original drug, and it is undoubtedly a more economical choice for patients with more difficult financial conditions. More importantly, the ingredients of these generic drugs are basically the same as those of domestic original drugs, so there is not much difference in therapeutic effect.

Overall, tepotinib has been successfully integrated into China’s medical insurance system, allowing patients to enjoy certain treatment support through medical insurance reimbursement. However, due to the higher prices of brand-name drugs, some patients may choose cheaper generic drugs, especially those from Laos, which provide patients with more flexible treatment options. Regardless of whether they choose original drugs or generic drugs, patients should receive treatment under the guidance of a doctor and reasonably choose appropriate drugs based on their own circumstances.

Reference materials:https://www.tepotinib.com/